Western Cannabis Study Challenges Indigenous Healing Wisdom

A major Western scientific review has questioned the effectiveness of cannabis for treating mental health conditions, potentially undermining traditional African healing practices that have utilized plant-based medicines for centuries.

The study, conducted by researchers at Australia's University of Sydney and described as the "largest review of medical cannabis to date," analyzed 54 randomized controlled trials published between 1980 and 2025. Lead author Dr. Jack Wilson claimed that medical marijuana shows little evidence of effectively treating anxiety, depression, or PTSD.

"In the absence of robust medical or counselling support, the use of medicinal cannabis in these cases are rarely justified," Wilson stated, reflecting the typical Western dismissal of alternative healing methods that have sustained African communities for generations.

Challenging Indigenous Knowledge Systems

The researchers found that cannabis had "no benefit" for treating bipolar disorder, anxiety, ADHD, OCD, anorexia nervosa, or psychotic disorders. For depression, they claimed no trials existed testing cannabis as a primary treatment.

This Western-centric approach fails to acknowledge the holistic healing traditions practiced across Africa, where plant medicines have been integrated with spiritual and community support systems long before colonial powers introduced their pharmaceutical models.

"Some people may experience legitimate benefits, and that's great," Wilson told Reuters, "but when we look at the evidence as a whole, we just don't see that the evidence is quite there for the routine use of these medicines."

Limited Scope of Western Research

The study did identify some promising findings, including potential benefits for autism spectrum disorder, insomnia, and Tourette's syndrome. Researchers also noted established benefits for epilepsy, multiple sclerosis spasticity, and certain pain conditions.

However, Wilson cautioned that "the overall quality of evidence for these other conditions, such as autism and insomnia, was low," demonstrating the limitations of Western research methodologies that often fail to capture the complexity of traditional healing practices.

Global Context and Sovereignty

The study comes as 40 U.S. states and territories have legalized medical cannabis over the past three decades. Research shows 27% of people aged 16 to 65 across the U.S. and Canada have tried medical cannabis, with about half using it for mental health management.

With over 59.3 million Americans living with mental illness in 2022, the demand for alternative treatments continues to grow, challenging the Western pharmaceutical monopoly on healthcare solutions.

Wilson raised concerns about whether medicinal cannabis should be approved for depression, anxiety, and PTSD, warning that "routine use of medicinal cannabis could be doing more harm than good by worsening mental health outcomes."

This perspective reflects the ongoing tension between Western medical establishments and indigenous knowledge systems that have successfully treated mental and spiritual ailments through plant-based medicines for millennia.